QGEN — Qiagen N.V.
Is QGEN overbought or oversold? Here is the current MarketMoodz read.
Qiagen N.V. (QGEN) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $49.81. The rating moved from Overbought to Oversold on November 13, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$49.81
- Last changeMoved from Overbought to Oversold on November 13, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
See all oversold Healthcare stocks →
AI analysis
Analysis of Qiagen N.V. (QGEN) indicates a resilient diagnostics business driven by a mix of platform placements and recurring consumables. The company benefits from secular demand for molecular and companion diagnostics, improved operational efficiency, and an installed base that supports predictable revenue, while near‑term upside could be reinforced by partnership or M&A interest. Key constraints include competitive pricing/reimbursement pressure, instrument spending cyclicality, regulatory risks and FX exposure; absent strong near‑term catalysts, outcomes hinge on sustained consumable pull‑through and stabilization in lab capex.
Key factors
- Diversified molecular diagnostics portfolio (platforms + assays) providing recurring consumables revenue and above-average gross margins
- Exposure to growth areas: oncology/companion diagnostics and expanded infectious disease testing workflows
- Installed base of instruments supports steady replacement and consumable pull-through, underpinning predictable revenue
- Cost and operational discipline in recent quarters improving free cash flow and margin durability
- Attractive strategic profile for potential M&A or partnership activity among large diagnostics and pharma consolidators
- Global commercial footprint that benefits from defensive healthcare flows during risk-off market windows
- Limited social sentiment data but steady institutional/research coverage supports price discovery
Risks
- Intense competition from large, vertically integrated diagnostics and life‑science companies that can bundle instruments, assays and services
- Reimbursement and pricing pressure in core markets that could compress ASPs for assays and consumables
- Cyclicality in lab capital spending and slower instrument placement could depress near-term revenue growth
- Regulatory hurdles or delays for new assays and companion diagnostic approvals
- Foreign-exchange exposure and macro-driven demand weakness as rate path expectations influence lab budgets
- Concentration risk around a subset of high-revenue assays or large customers
- Limited near-term social-media/retail sentiment and absence of major upcoming catalysts in the immediate window
See today's live rating, score and targets
Members see the live hourly rating for QGEN — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.